MD20150037A2 - Compuşi heteroaromatici şi utilizarea lor ca liganzi de dopamină D1 - Google Patents
Compuşi heteroaromatici şi utilizarea lor ca liganzi de dopamină D1Info
- Publication number
- MD20150037A2 MD20150037A2 MDA20150037A MD20150037A MD20150037A2 MD 20150037 A2 MD20150037 A2 MD 20150037A2 MD A20150037 A MDA20150037 A MD A20150037A MD 20150037 A MD20150037 A MD 20150037A MD 20150037 A2 MD20150037 A2 MD 20150037A2
- Authority
- MD
- Moldova
- Prior art keywords
- cognitive
- schizophrenia
- oxides
- preparation
- dopamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Prezenta invenţie se referă la compuşii cu formula (I):(I)şi sărurile farmaceutic acceptabile ale acestora şi N-oxizii celor menţionaţi mai sus; procedeele de preparare; compuşii intermediari folosiţi la preparare; compoziţiile ce conţin aceşti compuşi, săruri sau N-oxizi, şi utilizarea lor pentru tratamentul tulburărilor mediate de receptorii D1 sau al tulburărilor asociate cu medierea receptorilor D1, de exemplu, schizofrenie (simptomele sale cognitive şi negative), disfuncţia cognitivă (de exemplu, disfuncţia cognitivă asociată cu schizofrenia, AD, PD, sau terapie farmacoterapeutică), ADHD, impulsivitate, dependenţă compulsivă de jocuri de noroc, supraalimentare, tulburare din spectrul autismului, MCI, declin cognitiv legat de vârstă, demenţă, RLS, boala Parkinson, coree Huntington, anxietate, depresie, MDD, TRD, şi tulburare bipolară.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261723995P | 2012-11-08 | 2012-11-08 | |
PCT/IB2013/059768 WO2014072882A1 (en) | 2012-11-08 | 2013-10-30 | Heteroaromatic compounds as dopamine d1 ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
MD20150037A2 true MD20150037A2 (ro) | 2015-11-30 |
Family
ID=49955424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDA20150037A MD20150037A2 (ro) | 2012-11-08 | 2013-10-30 | Compuşi heteroaromatici şi utilizarea lor ca liganzi de dopamină D1 |
Country Status (30)
Country | Link |
---|---|
US (3) | US8822494B2 (ro) |
EP (1) | EP2917216B1 (ro) |
JP (1) | JP5823657B1 (ro) |
KR (1) | KR101660664B1 (ro) |
CN (1) | CN104837839A (ro) |
AP (1) | AP3861A (ro) |
AR (1) | AR095359A1 (ro) |
AU (1) | AU2013343105B2 (ro) |
BR (1) | BR112015010412A2 (ro) |
CA (1) | CA2889572C (ro) |
CL (1) | CL2015001233A1 (ro) |
CO (1) | CO7350619A2 (ro) |
CR (1) | CR20150237A (ro) |
EA (1) | EA201500402A1 (ro) |
ES (1) | ES2652514T3 (ro) |
GE (1) | GEP201606598B (ro) |
HK (1) | HK1213256A1 (ro) |
IL (1) | IL238712A0 (ro) |
MA (1) | MA38069A1 (ro) |
MD (1) | MD20150037A2 (ro) |
MX (1) | MX2015005506A (ro) |
NI (1) | NI201500066A (ro) |
PE (1) | PE20150966A1 (ro) |
PH (1) | PH12015500883A1 (ro) |
SG (1) | SG11201502884TA (ro) |
TN (1) | TN2015000167A1 (ro) |
TW (1) | TWI577678B (ro) |
UA (1) | UA111687C2 (ro) |
UY (1) | UY35129A (ro) |
WO (1) | WO2014072882A1 (ro) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013343104A1 (en) | 2012-11-08 | 2015-04-23 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
JP5823657B1 (ja) * | 2012-11-08 | 2015-11-25 | ファイザー・インク | ドーパミンd1リガンドとしての複素芳香族化合物 |
MA38661A1 (fr) | 2013-06-27 | 2017-03-31 | Pfizer | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine |
WO2015162515A1 (en) * | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
MX2016013969A (es) | 2014-04-25 | 2017-01-11 | Pfizer | Compuestos heteroaromaticos y su uso como ligandos de dopamina d1. |
WO2015162518A1 (en) * | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
CA2946990A1 (en) * | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heterocyclic compounds and their use as dopamine d1 ligands |
WO2015166370A1 (en) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
CN103992319B (zh) * | 2014-05-27 | 2015-09-16 | 天津市斯芬克司药物研发有限公司 | 一种吡啶羧酸类化合物的制备方法 |
CN111182898B (zh) * | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
AU2018290889A1 (en) | 2017-06-30 | 2020-02-13 | Chase Therapeutics Corporation | NK-1 antagonist compositions and methods for use in treating depression |
WO2021259831A1 (en) | 2020-06-22 | 2021-12-30 | F. Hoffmann-La Roche Ag | Sulfone derivatives |
WO2023143321A1 (zh) * | 2022-01-29 | 2023-08-03 | 苏州科睿思制药有限公司 | 他伐帕敦的晶型及其制备方法和用途 |
CN114751855B (zh) * | 2022-05-23 | 2024-05-07 | 上海皓鸿生物医药科技有限公司 | 一种2-溴-4-氨基-5-甲基吡啶的制备方法 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US6395733B1 (en) | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
SE0301906D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
NZ544200A (en) | 2003-07-14 | 2009-07-31 | Arena Pharm Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
JP5368701B2 (ja) | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | c−Metモジュレーター及び使用方法 |
ATE501148T1 (de) | 2004-12-14 | 2011-03-15 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
JP2008527031A (ja) * | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なピロロピリジン誘導体 |
WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
JP2009529047A (ja) | 2006-03-07 | 2009-08-13 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環系ピラゾール化合物およびその使用 |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
WO2008037607A1 (de) | 2006-09-25 | 2008-04-03 | Basf Se | Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen |
WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
WO2008089307A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
US20080200458A1 (en) | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
US8557830B2 (en) | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
US7829567B2 (en) | 2007-10-31 | 2010-11-09 | Kaohsiung Medical University | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same |
EP2229381A1 (en) | 2007-12-06 | 2010-09-22 | Schering Corporation | Gamma secretase modulators |
UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
UY31984A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
US20100063047A1 (en) | 2008-09-10 | 2010-03-11 | Kalypsys, Inc. | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
WO2010036629A2 (en) | 2008-09-26 | 2010-04-01 | National Health Research Institutes | Fused multicyclic compounds as protein kinase inhibitors |
PE20120506A1 (es) * | 2009-03-19 | 2012-05-14 | Medical Res Council Technology | Derivados de pirazolopiridina como inhibidores de quinasas |
WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
US9345699B2 (en) | 2009-06-09 | 2016-05-24 | Nantbioscience, Inc. | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
MX2012000817A (es) | 2009-07-21 | 2012-05-08 | Gilead Calistoga Llc | Tratamiento para desordenes del higado con inhibidores pi3k. |
TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
GB201008134D0 (en) | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
EP2588467A1 (en) | 2010-07-01 | 2013-05-08 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
JP2013533884A (ja) | 2010-07-02 | 2013-08-29 | アムジエン・インコーポレーテツド | Pi3k活性阻害剤としての複素環化合物およびそれらの使用 |
AU2013343104A1 (en) * | 2012-11-08 | 2015-04-23 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
JP5823657B1 (ja) * | 2012-11-08 | 2015-11-25 | ファイザー・インク | ドーパミンd1リガンドとしての複素芳香族化合物 |
-
2013
- 2013-10-30 JP JP2015540249A patent/JP5823657B1/ja active Active
- 2013-10-30 GE GEAP201313820A patent/GEP201606598B/en unknown
- 2013-10-30 AU AU2013343105A patent/AU2013343105B2/en not_active Ceased
- 2013-10-30 CA CA2889572A patent/CA2889572C/en active Active
- 2013-10-30 MX MX2015005506A patent/MX2015005506A/es unknown
- 2013-10-30 WO PCT/IB2013/059768 patent/WO2014072882A1/en active Application Filing
- 2013-10-30 AP AP2015008382A patent/AP3861A/en active
- 2013-10-30 KR KR1020157014721A patent/KR101660664B1/ko active IP Right Grant
- 2013-10-30 BR BR112015010412A patent/BR112015010412A2/pt not_active IP Right Cessation
- 2013-10-30 UA UAA201504509A patent/UA111687C2/uk unknown
- 2013-10-30 SG SG11201502884TA patent/SG11201502884TA/en unknown
- 2013-10-30 EA EA201500402A patent/EA201500402A1/ru unknown
- 2013-10-30 MD MDA20150037A patent/MD20150037A2/ro not_active Application Discontinuation
- 2013-10-30 CN CN201380063892.3A patent/CN104837839A/zh active Pending
- 2013-10-30 EP EP13820925.9A patent/EP2917216B1/en active Active
- 2013-10-30 PE PE2015000612A patent/PE20150966A1/es not_active Application Discontinuation
- 2013-10-30 ES ES13820925.9T patent/ES2652514T3/es active Active
- 2013-11-05 US US14/072,563 patent/US8822494B2/en active Active
- 2013-11-07 TW TW102140555A patent/TWI577678B/zh not_active IP Right Cessation
- 2013-11-07 AR ARP130104095A patent/AR095359A1/es unknown
- 2013-11-08 UY UY0001035129A patent/UY35129A/es not_active Application Discontinuation
-
2014
- 2014-07-23 US US14/339,123 patent/US9133190B2/en active Active
-
2015
- 2015-04-21 PH PH12015500883A patent/PH12015500883A1/en unknown
- 2015-04-30 TN TNP2015000167A patent/TN2015000167A1/fr unknown
- 2015-05-05 MA MA38069A patent/MA38069A1/fr unknown
- 2015-05-07 CL CL2015001233A patent/CL2015001233A1/es unknown
- 2015-05-07 IL IL238712A patent/IL238712A0/en unknown
- 2015-05-07 NI NI201500066A patent/NI201500066A/es unknown
- 2015-05-08 CR CR20150237A patent/CR20150237A/es unknown
- 2015-05-08 CO CO15105499A patent/CO7350619A2/es unknown
- 2015-08-06 US US14/819,541 patent/US9527843B2/en active Active
-
2016
- 2016-02-02 HK HK16101174.8A patent/HK1213256A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015500883A1 (en) | Heteroaromatic compounds as dopamide d1 ligands | |
PH12015502502A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
UY33382A (es) | Compuestos heterocíclicos de nitrógeno insaturados útiles como inhibidores de pde10 | |
MY165730A (en) | Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof | |
UA106692C2 (uk) | ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ | |
TN2011000221A1 (en) | Pyrazine compounds as phosphodiesterase 10 inhibitors | |
MX2009013935A (es) | Compuestos quimicos. | |
JO3316B1 (ar) | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل | |
TN2015000018A1 (en) | 5-ht3 receptor antagonists | |
GEP201706659B (en) | Novel bicyclic pyridinones | |
TN2014000058A1 (en) | A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes | |
MX2010005649A (es) | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. | |
PH12016501863A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
PH12015500860A1 (en) | 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders | |
MX2018008653A (es) | Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina . | |
PH12016501993A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
GEP201706655B (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
TN2012000191A1 (en) | Quinuclidine compounds as alpha-7nicotinic acetylcholine receptor ligands | |
MX2012004317A (es) | Com puestos de azabiciclo[2.2.1] heptano como ligandos de receptor de acetilcolina alfa-7-nicotinico. | |
IN2014DN09826A (ro) | ||
MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
PH12014502780A1 (en) | Azetidine and piperidine compounds useful as pde10 inhibitors | |
GEP20156227B (en) | Azabicyclo[3.1.0]hex-2-yl derivatives, method for preparing same, and pharmaceutical compositions containing same | |
IN2012DE00262A (ro) | ||
GEP20135801B (en) | New compounds of azabicyclo[3.2.0]hept-3-yl, method for preparing same and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA9A | Abandonment or withdrawal of application (patent for invention) |